4,6-Dimethyl-2-(methylthio)pyrimidine, 95.0%, 100g

(2,3-Dihydro-1h-inden-5-yl)boronic acid, 95%, 100mg

3,3'-Diethylthiacarbocyanine Iodide>98.0%(HPLC)(N)5g

5-Bromo-6-fluoronicotinic acid, 95.0%, 10g

7-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole, 98+%, 500mg

3,4-dihydropyrimidine-4-thione, 97%, 1g

Ethyl Arachidate>95.0%(GC)25g

tert-Butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate, 95.0%, 250mg

(1S,2S)-(+)-1,2-Cyclohexanediamino-N,N'-bis(3,5-di-t-butylsalicylidene)cobalt(III) p-toluenesulfonate, 97%, 5g

3-(3-METHOXY-PHENOXY)-PROPYLAMINE HCL, 95.0%, 1g

3,4-dichloro-4'-(3-pyrrolinomethyl) benzophenone, 97.0%, 1g

(5-Bromothiophen-2-yl)methanamine hydrochloride, 95.0%, 250mg

GC-Kapillarsäule ROTI®Cap-1701 MS, L 60 m, Ø-Innen 0,32 mm, Filmd. 0,25 µm, 1 Stück